ANIK / Anika Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Reports Second Quarter 2025 Financial Results Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to mo

EXHIBIT 99.1 Anika Reports Second Quarter 2025 Financial Results Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end poi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance

EXHIBIT 99.1 Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant im

Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 20, 2025)

Exhibit 10.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 20, 2025) Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants and advisors, and to motivate suc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2025 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2025 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of incorporation or organizati

Form of Notice of Grant of Market Phantom Performance Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

Exhibit 10.1b NOTICE OF GRANT OF PERFORMANCE RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”), to the Grantee designated in th

Form of Notice of Grant of Strategic Phantom Performance Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

Exhibit 10.1a NOTICE OF GRANT OF PERFORMANCE RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”), to the Grantee designated in th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, In

Anika Reports First Quarter 2025 Financial Results First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones

EXHIBIT 99.1 Anika Reports First Quarter 2025 Financial Results First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Anika Therapeutics, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934               Filed by the Registrant ☒     Filed by a party other than the Registrant  ☐               Check the appropriate box:  ☐ 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

List of Subsidiaries of Anika Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Formation Anika Securities, Inc. Massachusetts Anika Therapeutics Limited United Kingdom Anika Therapeutics S.r.l. (Formerly: Fidia Advanced Biopolymers S.r.l.) Italy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutic

Executive Retention Agreement, dated December 12, 2024, by and between Anika Therapeutics, Inc. and David Colleran

Exhibit 10.13 ANIKA THERAPEUTICS, INC. EXECUTIVE RETENTION AGREEMENT Anika Therapeutics, Inc., a Delaware corporation (the “Company”), and David Colleran (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of December 12, 2024 (the “Effective Date”). WHEREAS, the Company desires to provide and the Executive desires to accept the severance protections provided

Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

Exhibit 10.10l NOTICE OF GRANT OF RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”), to the Grantee designated in this Notice o

Executive Retention Agreement, dated December 12, 2024, by and between Anika Therapeutics, Inc. and Steve Griffin

Exhibit 10.15 ANIKA THERAPEUTICS, INC. EXECUTIVE RETENTION AGREEMENT Anika Therapeutics, Inc., a Delaware corporation (the “Company”), and Steve Griffin (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of December 12, 2024 (the “Effective Date”). WHEREAS, the Company desires to provide and the Executive desires to accept the severance protections provided

Restated Insider Trading Policy

Exhibit 19 ANIKA THERAPEUTICS, INC. Restated Insider Trading Policy The Board of Directors (the “Board”) of Anika Therapeutics, Inc. (including its subsidiaries, “Anika”) has approved this Restated Insider Trading Policy (this “Policy”). The objective of this Policy is to help prevent insider trading or allegations of insider trading, and to protect Anika’s reputation for integrity and ethical con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Anika Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant

EXHIBIT 99.1 Anika Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Int

Anika Completes Divestiture of Parcus Medical Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio

EXHIBIT 99.1 Anika Completes Divestiture of Parcus Medical Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on earl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics

Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Reports Third Quarter 2024 Financial Results Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwi

EXHIBIT 99.1 Anika Reports Third Quarter 2024 Financial Results Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Anika Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations

EXHIBIT 99.1 Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile BEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint pres

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Reports Second Quarter 2024 Financial Results Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating signi

EXHIBIT 99.1 Anika Reports Second Quarter 2024 Financial Results Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand Delivered revenue in line with expectations with 15% adjusted EBITDA margins; Strong first half 2024 international O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2024 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of incorporation or organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐

Anika Therapeutics, Inc. 2021 Inducement Plan (as amended on May 2, 2024)

Exhibit 99.1 ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN (As amended May 2, 2024) Anika Therapeutics, Inc. sets forth herein the terms of its 2021 Inducement Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain Eligible Individuals by providing an inducement material to Eligible Individuals to enter into employment with the Company

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anika Therapeutics, Inc.

As filed with the Securities and Exchange Commission on May 31, 2024

As filed with the Securities and Exchange Commission on May 31, 2024 Registration No.

ANIK / Anika Therapeutics, Inc. / Caligan Partners LP - ANIKA THERAPEUTICS, INC. Activist Investment

SC 13D/A 1 p24-1952sc13da.htm ANIKA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3) Anika Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission F

Anika Enters into Cooperation Agreement with Caligan Partners Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program

EXHIBIT 99.1 Anika Enters into Cooperation Agreement with Caligan Partners Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a coope

Cooperation Agreement, dated May 28, 2024, by and among Anika Therapeutics, Inc. and Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson

Exhibit 10.1 Execution Version COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of May 28, 2024, by and between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson, (collectively with each of their respective Affiliates and Associates, the “Investor Group”). Unless ot

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

Transitional Services and Separation Agreement dated as of May 2, 2024 between Anika Therapeutics, Inc. and Michael Levitz

Exhibit 10.3 May 2, 2024 Michael Levitz Re: Transitional Services and Separation Agreement Dear Michael, This letter agreement follows our conversations regarding your employment with Anika Therapeutics, Inc. (the “Company”). This confirms that you will be transitioning and resigning from your employment. We appreciate your contributions and would like to work with you to make this transition as s

Executive Retention Agreement effective as of June 3, 2024 between Anika Therapeutics, Inc. and Stephen Griffin

Exhibit 10.2 ANIKA THERAPEUTICS, INC. EXECUTIVE RETENTION AGREEMENT Anika Therapeutics, Inc., a Delaware corporation (the “Company”), and Stephen Griffin (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of June 3, 2024 (the “Effective Date”). WHEREAS, the Company desires to provide and the Executive desires to accept the severance protections provided here

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, In

Anika Announces CFO Transition Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024

EXHIBIT 99.1 Anika Announces CFO Transition Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer (“CFO

Anika Reports First Quarter 2024 Financial Results Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million

EXHIBIT 99.1 Anika Reports First Quarter 2024 Financial Results Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint pre

Offer letter dated as of May 2, 2024 between Anika Therapeutics, Inc. and Stephen Griffin

Exhibit 10.1 May 2, 2024 Stephen Griffin 7030 Elizabeth Drive McLean, VA 22101 Dear Stephen: I am pleased to confirm our offer to you to join Anika Therapeutics, Inc. (“Anika” or the “Company”). We are excited about the prospect of having you join our team and look forward to the addition of your professionalism and experience to help the Company achieve its goals. This letter summarizes the initi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

Exhibit 10.10(a) NOTICE OF GRANT OF RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”), to the Grantee designated in this Notice

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

-12-31FY2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N

Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

Exhibit 10.10(b) NOTICE OF GRANT OF RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended from time to time (the “Plan”), to the Grantee designated in this Notice of Grant of R

Anika Therapeutics, Inc. Compensation Recovery Policy adopted on November 27, 2023

Exhibit 97 ANIKA THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Anika Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordanc

Anika Therapeutics, Inc. Non-Employee Director Compensation Policy (restated as of December 22, 2023)

Exhibit 10.8 Anika Therapeutics, Inc. Restated Director Compensation Policy The Board of Directors (the “Board”) of Anika Therapeutics, Inc. (including its subsidiaries, “Anika”) has approved this Restated Director Compensation Policy (this “Policy”) in order to provide a total compensation package that enables Anika to attract and retain, on a long-term basis, high caliber directors to serve on t

Executive Retention Agreement, dated September 27, 2021, by and between Anika Therapeutics, Inc. and Anne Nunes

Exhibit 10.14 ANIKA THERAPEUTICS, INC. EXECUTIVE RETENTION AGREEMENT Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and Anne Nunes (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of September 27, 2021 (the “Effective Date”). Whereas, the Company desires to provide and the Executive desires to accept the severance protections provid

List of Subsidiaries of Anika Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Formation Anika Securities, Inc. Massachusetts Anika Therapeutics Limited United Kingdom Anika Therapeutics S.r.l. (Formerly: Fidia Advanced Biopolymers S.r.l.) Italy ArthroSurface Incorporated Delaware Parcus Medical, LLC Wisconsin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 Anika Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Reports Fourth Quarter and Year-End 2023 Financial Results Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announce

EXHIBIT 99.1 Anika Reports Fourth Quarter and Year-End 2023 Financial Results Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $

FORM OF NOMINEE AGREEMENT

EXHIBIT 99.3 FORM OF NOMINEE AGREEMENT 1. This Nomination Agreement (the “Agreement”) is by and between Caligan Partners, LP (“Caligan,” “we” or “us”) and [NOMINEE] (“you”). 2. You agree that you are willing, should we so elect, to become a member of a slate of nominees (the “Slate”) of a Caligan affiliate (the “Nominating Party”), which nominees shall stand for election as directors of Anika Ther

Joint Filing Agreement PURSUANT TO RULE 13d-1(k)

EX-99 2 p24-1111exhibit992.htm JOINT FILING AGREEMENT EXHIBIT 99.2 Joint Filing Agreement PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing addi

ANIK / Anika Therapeutics, Inc. / Caligan Partners LP - ANIKA THERAPEUTICS, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2) Anika Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 035255108 (CUSIP Number) D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2024 Anika Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2024 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or other jurisdiction of incorporation) (Commiss

ANIK / Anika Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0293-anikatherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Anika Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 035255108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to d

ANIK / Anika Therapeutics, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11 )* Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

EXHIBIT 1: Agreement to Make a Joint Filing

EX-1 2 tm243940d1ex-1.htm EXHIBIT 1 CUSIP No. 035255108 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G February 9, 2024 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statemen

ANIK / Anika Therapeutics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 tm243940d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANIKA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value of $0.01 Per Share (Title of Class of Securities) 035255108 (CUSIP Number) December 31

Anika Therapeutics, Inc. 2021 Inducement Plan (as amended on December 22, 2023)

Exhibit 99.1 ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN Anika Therapeutics, Inc. sets forth herein the terms of its 2021 Inducement Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain Eligible Individuals by providing an inducement material to Eligible Individuals to enter into employment with the Company or an Affiliate, by provi

As filed with the Securities and Exchange Commission on January 22, 2024

As filed with the Securities and Exchange Commission on January 22, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anika Therapeutics, Inc.

As filed with the Securities and Exchange Commission on January 19, 2024

As filed with the Securities and Exchange Commission on January 19, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business Revenue Growth Exceeded Expectations in the Third Quarter and Year-To-Date, with Joint Preservation and Restoratio

EXHIBIT 99.1 Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business Revenue Growth Exceeded Expectations in the Third Quarter and Year-To-Date, with Joint Preservation and Restoration up 14% and 10% and OA Pain Management up 2% and 11%, Respectively RevoMotion™ Reverse Shoulder Arthroplasty System Fully Launched at OS

Anika. Restore Active Living. ΠSIDOTI SMALL CAP INVESTOR CONFERENCE INVESTOR OVERVIEW SEPTEMBER 21, 2023 Safe Harbor Statements 2 Cautionary Note on Forward - looking Statements The statements made in, and during the course of, this presentation tha

Exhibit 99.1 Anika. Restore Active Living. Œ SIDOTI SMALL CAP INVESTOR CONFERENCE INVESTOR OVERVIEW SEPTEMBER 21, 2023 Safe Harbor Statements 2 Cautionary Note on Forward - looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, it

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commis

ANIK / Anika Therapeutics Inc. / Caligan Partners LP - ANIKA THERAPEUTICS, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1) Anika Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 035255108 (CUSIP Number) D

ANIK / Anika Therapeutics Inc. / Caligan Partners LP - ANIKA THERAPEUTICS, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* Anika Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 035255108 (CUSIP Number) Dav

Anika Reports Second Quarter 2023 Financial Results Double Digit Q2 Revenue Growth Driven by Strong OA Pain Management Growth of 22%; Raising Low-End of Full-Year Guidance Range on Positive Year-to-Date Performance Hyalofast®, Single-Stage, Off-the-S

EXHIBIT 99.1 Anika Reports Second Quarter 2023 Financial Results Double Digit Q2 Revenue Growth Driven by Strong OA Pain Management Growth of 22%; Raising Low-End of Full-Year Guidance Range on Positive Year-to-Date Performance Hyalofast®, Single-Stage, Off-the-Shelf, Resorbable Hyaluronic Acid Scaffold for Cartilage Repair, Pivotal Phase III Trial Fully Enrolled; Modular PMA Submission on Track t

As filed with the Securities and Exchange Commission on August 8, 2023

As filed with the Securities and Exchange Commission on August 8, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Anika Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anika Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2023 (June 14, 2023) Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of Commission

Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 14, 2023)

Exhibit 10.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 14, 2023) Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants and advisors, and to motivate suc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Anika Therapeutics, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

Anika Reports First Quarter 2023 Financial Results Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11%

EXHIBIT 99.1 Anika Reports First Quarter 2023 Financial Results Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11% BEDFORD, Mass., May 09, 2023 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d480900ddefa14a.htm DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY S TATEME NT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY S TATEME NT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY S TATEME NT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY S TATEME NT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Conf

Cooperation Agreement, dated April 13, 2023, by and among the Company and Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on April 13, 2023)

EX-10.1 Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of April 13, 2023, by and between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson, (collectively with each of their respective Affiliates and Associates, the “Investor Group”). Unless otherwise

Anika Enters Into Cooperation Agreement with Caligan Partners Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee

EX-99.1 Exhibit 99.1 Anika Enters Into Cooperation Agreement with Caligan Partners Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee Bedford, Mass., April 13, 2023 – Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or other jurisdiction of incorporation) (Commission

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Revised Preliminar

Goodwin Procter LLP

CORRESP Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 April 5, 2023 Mr. Daniel Duchovny Office of Mergers and Acquisitions Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Anika Therapeutics, Inc. Preliminary Proxy Statement filed on March 27, 2023 File No. 001-14027 Dear Mr. Duchovny: This le

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant þ Check the appropriate box: þ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Under Rule 14a-12 Anika Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

Description of Securities of Anika Therapeutics, Inc.

Exhibit 4.1 DESCRIPTION OF SECURITIES Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”): common stock, $0.01 par value per share (“Common Stock”). Authorized Capital Stock We are authorized to issue two classes of capital stock to be designated as the Commo

List of Subsidiaries of Anika Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Formation Anika Securities, Inc. Massachusetts Anika Therapeutics Limited United Kingdom Anika Therapeutics S.r.l. (Formerly: Fidia Advanced Biopolymers S.r.l.) Italy ArthroSurface Incorporated Delaware Parcus Medical, LLC Wisconsin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutic

Executive Retention Agreement, dated March 9, 2020, by and between Anika Therapeutics, Inc. and David Colleran

Exhibit 10.13 ANIKA THERAPEUTICS, INC. EXECUTIVE RETENTION AGREEMENT Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and [David Colleran] (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of March 9th, 2020 (the “Effective Date”). Whereas, the Company desires to provide and the Executive desires to accept the severance protections pro

Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6% Completed First Surgeries and Initiated Limited Market Release of New RevoMotion™ Reverse S

EXHIBIT 99.1 Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6% Completed First Surgeries and Initiated Limited Market Release of New RevoMotion™ Reverse Shoulder Arthroplasty System Commenced Full Market Release of X-Twist™ Fixation System in Sports Medicine Hyalofast®, Anika’s Off-the-Shel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Anika Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials x Soliciting Material Under Rule 14a-12 Anika Therapeutics, Inc.

to Schedule 13G

EX-99.I 2 d401798dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –

to Schedule 13G Joint Filing Agreement

EX-99.II 3 d401798dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2023, in connection with their beneficial ownership of Anika Therapeutics Inc. Each of, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameripr

ANIK / Anika Therapeutics Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment

SC 13G/A 1 d401798dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #2 Under the Securities and Exchange Act of 1934 Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

ANIK / Anika Therapeutics Inc / Trigran Investments, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 tm235856d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANIKA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value of $0.01 Per Share (Title of Class of Securities) 035255108 (CUSIP Number) December 31

ANIK / Anika Therapeutics Inc / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

February 10, 2023

EX-99.1 2 tm235856d6ex99-1.htm EXHIBIT 1 CUSIP No. 035255108 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G February 10, 2023 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this st

ANIK / Anika Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0267-anikatherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Anika Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 035255108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Reports Third Quarter Fiscal 2022 Financial Results Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alo

EXHIBIT 99.1 Anika Reports Third Quarter Fiscal 2022 Financial Results Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal?, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone Pivotal Phase III Clinical Trial for Hyalofast?, HA-Based, Single-Stage Cartilage Repair Product, Reaches 96% Enrollment Positive Feed

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or other jurisdiction of incorporation) (Commissi

Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthrit

Exhibit 99.1 Anika?s Cingal? Successfully Achieves Primary Endpoint in Third Phase III Study Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks Study Builds on Prior Phase III Study Data that Demonstrated Superiority over Placebo and Hyaluronic Acid-Base

ANIK / Anika Therapeutics Inc / Trigran Investments, Inc. - SC 13G Passive Investment

SC 13G 1 tm2227546d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No.)* ANIKA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value of $0.01 Per Share (Title of Class of Securities) 035255108 (CUSIP Number) September 20, 202

EXHIBIT 1: Agreement to Make a Joint Filing

EX-1 2 tm2227546d2ex1.htm EXHIBIT 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G October 6, 2022 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statement on Schedule 13G (including any and all amend

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anika Therapeutics, Inc.

As filed with the Securities and Exchange Commission on August 4, 2022

As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc

Anika Reports Second Quarter Fiscal 2022 Financial Results Second quarter revenue growth up 4% X-Twist™ 510(k) clearance received; Limited market release on schedule for 2H 2022

EXHIBIT 99.1 Anika Reports Second Quarter Fiscal 2022 Financial Results Second quarter revenue growth up 4% X-Twist? 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its second

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 8, 2022)

Exhibit 10.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 8, 2022) Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants and advisors, and to motivate such

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2022 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of incorporation or organizatio

ANIK / Anika Therapeutics Inc / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

Anika Reports First Quarter Fiscal 2022 Financial Results First quarter revenue growth of 7% year-over-year driven by favorable order timing in OA Pain Management

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Anika Reports First Quarter Fiscal 2022 Financial Results First quarter revenue growth of 7% year-over-year driven by favorable order timing in OA Pain Management BEDFORD, Mass., May 05, 2022 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial resu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Executive Retention Agreement, dated August 10, 2020, by and between Anika Therapeutics, Inc. and Michael Levitz

Exhibit 10.12

Lease Agreement, dated May 25, 2017, between High Properties and Parcus Medical, LLC relating to 6455 Parkland Drive, Suite 101, Sarasota, FL

Exhibit 10.3c

Form of Notice of Grant of Restricted Stock Units Award, including Terms and Conditions of Restricted Stock Award, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

Exhibit 10.10(j) NOTICE OF GRANT OF RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the ?Company?) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended from time to time (the ?Plan?), to the Grantee designated in this Notice of Grant of R

Form of Notice of Grant of Deferred Stock Awards Units, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

EX-10.10K 8 ex342578.htm EXHIBIT 10.10K Exhibit 10.10(k) NOTICE OF GRANT OF DEFERRED STOCK UNITS ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended from time to time (the “Plan”), to the Grantee d

Amendment #1 to the Lease, Renewal Amendement, dated January 4, 2018, between High Properties and Parcus Medical LLC relating to 6423 Parkland Drive, Suites 101 and 102, Sarasota, FL

Exhibit 10.3b

Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

Exhibit 10.10(i) NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTION ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the ?Company?) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended from time to time (the ?Plan?), to the Grantee designated in this Notice of Grant

List of Subsidiaries of Anika Therapeutics, Inc.

EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Formation Anika Securities, Inc. Massachusetts Anika Therapeutics Limited United Kingdom Anika Therapeutics S.r.l. Italy (Formerly: Fidia Advanced Biopolymers S.r.l.) ArthroSurface Incorporated Delaware Parcus Medical, LLC Wisconsin

Anika Therapeutics, Inc. Non-Employee Director Compensation Policy (restated as of February 9, 2022)

Exhibit 10.8 Anika Therapeutics, Inc. Restated Director Compensation Policy The Board of Directors (the ?Board?) of Anika Therapeutics, Inc. (including its subsidiaries, ?Anika?) has approved this Restated Director Compensation Policy (this ?Policy?) effective as of February 9, 2022. The objective of this Policy is to provide a total compensation package that enables Anika to attract and retain, o

Lease Agreement, dated November 26, 2012, between High Properties and Parcus Medical LLC relating to 6423 Parkland Drive, Suites 101 and 102, Sarasota, FL

Exhibit 10.3a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutic

Anika Reports Fourth Quarter and Year-End 2021 Financial Results Fourth quarter revenue growth of 10% year-over-year despite COVID headwinds Full-year 2021 revenue up 13% driven by strong growth in Joint Preservation and Restoration

EXHIBIT 99.1 Anika Reports Fourth Quarter and Year-End 2021 Financial Results Fourth quarter revenue growth of 10% year-over-year despite COVID headwinds Full-year 2021 revenue up 13% driven by strong growth in Joint Preservation and Restoration BEDFORD, Mass., March 08, 2022 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention ortho

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

to Schedule 13G

Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser ? Columbia Wanger Asset Management, LL

ANIK / Anika Therapeutics Inc / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

to Schedule 13G Joint Filing Agreement

Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2022, in connection with their beneficial ownership of Anika Therapeutics Inc.

ANIK / Anika Therapeutics Inc / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

ANIK / Anika Therapeutics Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file

ANIK / Anika Therapeutics Inc / RENAISSANCE TECHNOLOGIES LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anika Therapeutics, Inc. - (Name of Issuer) Common Stock, par value $0.01 per share - (Title of Class of Securities) 035255108 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

ANIK / Anika Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Anika Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 035255108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file

ANIK / Anika Therapeutics Inc / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Third Amendment to Credit Agreement dated as of November 12, 2021, by and among Anika Therapeutics, Inc., the Subsidiary Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., as administrative agent, L/C Issuer and Swingline Lender, and the other parties thereto

Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT, dated as of November 12, 2021 (this ?Third Amendment?), is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation (the ?Borrower?), the Subsidiary Guarantors party hereto, each lender party hereto, and the Administrative Agent (as defined below), and modifies that certain Credit Agreement, dated

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commiss

As filed with the Securities and Exchange Commission on November 5, 2021

As filed with the Securities and Exchange Commission on November 5, 2021 Registration No.

Anika Therapeutics, Inc. 2021 Inducement Plan (adopted November 4, 2021)

Exhibit 10.1 ANIKA THERAPEUTICS, INC. 2021 INDUCEMENT PLAN (As adopted by the Board of Directors November 4, 2021) Anika Therapeutics, Inc. sets forth herein the terms of its 2021 Inducement Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain Eligible Individuals by providing an inducement material to Eligible Individuals to enter in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 10.2 DESCRIPTION OF SECURITIES Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?): common stock, $0.01 par value per share (?Common Stock?). Authorized Capital Stock We are authorized to issue two classes of capital stock to be designated as the Comm

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Reports Third Quarter 2021 Financial Results Revenue growth of 25% year-over-year Company revises revenue growth outlook for 2021 to 9-11% on COVID Delta headwinds

EXHIBIT 99.1 Anika Reports Third Quarter 2021 Financial Results Revenue growth of 25% year-over-year Company revises revenue growth outlook for 2021 to 9-11% on COVID Delta headwinds BEDFORD, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its third quarter e

Anika Appoints Sheryl Conley to Board of Directors Appointment brings experienced orthopedic industry commercial leader to Anika’s Board

EXHIBIT 99.1 Anika Appoints Sheryl Conley to Board of Directors Appointment brings experienced orthopedic industry commercial leader to Anika?s Board BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as indepe

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

As filed with the Securities and Exchange Commission on August 6, 2021

As filed with the Securities and Exchange Commission on August 6, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc

As filed with the Securities and Exchange Commission on August 6, 2021

As filed with the Securities and Exchange Commission on August 6, 2021 Registration No.

Anika Reports Second Quarter 2021 Financial Results Revenue growth of 24% year-over-year Company raises full year revenue growth outlook to 11-14%

EXHIBIT 99.1 Anika Reports Second Quarter 2021 Financial Results Revenue growth of 24% year-over-year Company raises full year revenue growth outlook to 11-14% BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its second quarter ended June 30, 2021. Se

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of incorporation or organizati

ANIKA THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN

EXHIBIT 99.2 ANIKA THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN Article 1 - Purpose. This 2021 Employee Stock Purchase Plan (the ?Plan?) is intended to encourage stock ownership by all eligible employees of Anika Therapeutics, Inc., a Delaware corporation (including any successor corporation, the ?Company?), and its participating subsidiaries (as defined in Article 17) so that they may sha

ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 16, 2021)

EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 16, 2021) Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of Commission file number (I.R

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, In

Anika Reports First Quarter 2021 Financial Results Revenue lower by 3% versus pre-COVID in prior year Joint Preservation revenue up 55% as transformative mix shift continues Company on track to achieve stated revenue growth in 2021

EXHIBIT 99.1 Anika Reports First Quarter 2021 Financial Results Revenue lower by 3% versus pre-COVID in prior year Joint Preservation revenue up 55% as transformative mix shift continues Company on track to achieve stated revenue growth in 2021 BEDFORD, Mass., May 06, 2021 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthoped

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Annual Report - FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-140

Form of Notice of Grant of Incentive Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.

EX-10.13D 6 ex231631.htm EXHIBIT 10.13(D) Exhibit 10.13(d) NOTICE OF GRANT OF INCENTIVE STOCK OPTION ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”)

Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

EX-10.13G 8 ex231633.htm EXHIBIT 10.13(G) Exhibit 10.13(g) NOTICE OF GRANT OF RESTRICTED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”)

Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

Exhibit 10.13(e) NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTION ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the ?Company?) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), to the Grantee designated in this No

Form of Notice of Grant of Deferred Stock Awards Units, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

EX-10.13H 9 ex231634.htm EXHIBIT 10.13(H) Exhibit 10.13(h) NOTICE OF GRANT OF DEFERRED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended from time to time (the “Plan”),

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutic

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14027 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Reports Fourth Quarter and Year-End 2020 Financial Results Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Anika Reports Fourth Quarter and Year-End 2020 Financial Results Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021 BEDFORD, Mass., March 04, 2021 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and deli

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date of Event W

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Thi

to Schedule 13G

EX-99.I 2 d90150dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser – C

to Schedule 13G Joint Filing Agreement

EX-99.II 3 d90150dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 12, 2021 in connection with their beneficial ownership of Anika Therapeutics Inc. Each of, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameripris

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Anika Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Anika Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 035255108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is file

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutics

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Reports Third-Quarter 2020 Financial Results Revenue Increased 7% Year-over-Year to $31.7 Million Repaid $25 Million of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio

EXHIBIT 99.1 Anika Reports Third-Quarter 2020 Financial Results Revenue Increased 7% Year-over-Year to $31.7 Million Repaid $25 Million of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio BEDFORD, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancemen

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commissi

Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints System designed to alleviate pain and restore function and mobility of the wrist joint

EXHIBIT 99.1 Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints System designed to alleviate pain and restore function and mobility of the wrist joint BEDFORD, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advanceme

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commiss

Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board

EXHIBIT 99.1 Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board BEDFORD, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, resto

ANIK / Anika Therapeutics Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 05)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) July 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutics, Inc

Quarterly Report - FORM 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anik

ANIK / Anika Therapeutics Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) July 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Anika Appoints Michael Levitz as Chief Financial Officer Seasoned financial executive brings broad medical device industry experience and track record of value creation

EXHIBIT 99.1 Anika Appoints Michael Levitz as Chief Financial Officer Seasoned financial executive brings broad medical device industry experience and track record of value creation BEDFORD, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic earl

Offer letter dated as of July 29, 2020 between Anika Therapeutics, Inc. and Michael Levitz

Exhibit 10.1 July 29, 2020 Michael Levitz Dear Michael: I am pleased to confirm our offer to you to join Anika Therapeutics, Inc. (“Anika” or the “Company”). We are excited about the prospect of having you join our team and look forward to the addition of your professionalism and experience to help the Company achieve its goals. This letter summarizes the initial terms of our offer for your employ

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2020 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fil

Anika Reports Second Quarter 2020 Financial Results Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports

EXHIBIT 99.1 Anika Reports Second Quarter 2020 Financial Results Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020 BEDFORD, Mass., July 30, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, int

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 30, 2020 Anika Therapeutics (Exact Name of Registrant as Specified in Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

- S-8

As filed with the Securities and Exchange Commission on June 19, 2020 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) - Delaware 000-21326 04-3145961 (State or other jurisdiction of Commission file number (I

ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 16, 2020)

Exhibit 99.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN (As amended June 16, 2020) Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants and advisors, and to motivate suc

Anika Announces Planned CFO Transition Sylvia Cheung to Step Down in August 2020 Company Initiates Search for Successor

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Anika Announces Planned CFO Transition Sylvia Cheung to Step Down in August 2020 Company Initiates Search for Successor BEDFORD, Mass., June 02, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products across the orthopedic early intervention continuum of

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 27, 2020 Anika Therapeutics (Exact Name of Registrant as Specified in Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission File Number

Second Amendment effective May 14, 2020, with respect to the Credit Agreement dated as of October 24, 2017 and the Security and Pledge Agreement dated as of October 24, 2017

EX-10.4 3 exh104.htm EXHIBIT 10.4 Exhibit 10.4 EXECUTION VERSION SECOND AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO SECURITY AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO SECURITY AGREEMENT (this “Agreement”) dated as of May 14, 2020, by and among ANIKA THERAPEUTICS, INC., a Delaware corporation (formerly known as Anika Therapeutics, Inc., a Massachusetts corp

First Amendment effective August 13, 2019, with respect to the Credit Agreement dated as of October 24, 2017 and the Security and Pledge Agreement dated as of October 24, 2017

Exhibit 10.3 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Agreement”) dated as of August 13, 2019 (the “Effective Date”), is made by ANIKA THERAPEUTICS, INC., a Delaware corporation (formerly known as Anika Therapeutics, Inc., a Massachusetts corporation, the “Borrower”) in favor of, and for the benefit of, the Lenders (as defined in the Credit Agreement refe

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutics, In

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission Fi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 7, 2020 Anika Therapeutics (Exact Name of Registrant as Specified in Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Anika Reports First Quarter 2020 Financial Results Total Revenue Increases 43% Year-over-Year Continued Progress on Integration of Parcus Medical and Arthrosurface Acquisitions Withdrawing Full Year 2020 Financial Guidance Well Positioned to Manage t

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Anika Reports First Quarter 2020 Financial Results Total Revenue Increases 43% Year-over-Year Continued Progress on Integration of Parcus Medical and Arthrosurface Acquisitions Withdrawing Full Year 2020 Financial Guidance Well Positioned to Manage through COVID-19 Pandemic BEDFORD, Mass., May 07, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NAS

Employment Agreement, dated April 23, 2020, by and between Anika Therapeutics, Inc., and Dr. Cheryl R. Blanchard

Exhibit 10.1 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) shall be effective as of April 23, 2020 between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), and Cheryl R. Blanchard (the “Executive”). WHEREAS, the Executive is currently serving as Interim Chief Executive Officer of the Company; WHEREAS, the Company and the Executive are currently par

- DEFINITIVE ADDITIONAL MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant R Filed by a Party other than the Registrant £ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2020 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission

Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer Seasoned industry executive with experience leading global joint preservation and restoration businesses

Exhibit 99.1 Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer Seasoned industry executive with experience leading global joint preservation and restoration businesses BEDFORD, Mass.-(BUSINESS WIRE)- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic a

Anika Takes Actions to Strengthen Liquidity in Light of COVID-19

EXHIBIT 99.1 Anika Takes Actions to Strengthen Liquidity in Light of COVID-19 BEDFORD, Mass., April 08, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform, today provided an update on actions it is taking to strengthen liquidit

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 8, 2020 Anika Therapeutics (Exact Name of Registrant as Specified in Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other jurisdiction of Commission file number

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On February 3, 2020, (the “Closing Date”), Anika Therapeutics, Inc. (the “Company” or “Anika”) completed the acquisition of Arthrosurface Incorporated, a Delaware corporation (“Arthrosurface”) pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Arthrosurface Merger Agreement”), by and

Arthrosurface, Inc. Financial Statements Years Ended December 31, 2018 and 2017 Arthrosurface, Inc.

Exhibit 99.1 Arthrosurface, Inc. Financial Statements Years Ended December 31, 2018 and 2017 Arthrosurface, Inc. Financial Statements Years Ended December 31, 2018 and 2017 Arthrosurface, Inc. Contents Independent Auditor’s Report 3-4 Financial Statements Balance Sheets 6-7 Statements of Operations 8 Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity 9 Statements of Cash

PARCUS MEDICAL, LLC FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018 AND SEPTEMBER 30, 2019 FOR THE YEAR ENDED DECEMBER 31, 2018 AND PERIOD ENDED SEPTEMBER 30, 2019 PARCUS MEDICAL, LLC TABLE OF CONTENTS DECEMBER 31, 2018 AND SEPTEMBER 30, 2019

Exhibit 99.1 PARCUS MEDICAL, LLC FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018 AND SEPTEMBER 30, 2019 FOR THE YEAR ENDED DECEMBER 31, 2018 AND PERIOD ENDED SEPTEMBER 30, 2019 PARCUS MEDICAL, LLC TABLE OF CONTENTS DECEMBER 31, 2018 AND SEPTEMBER 30, 2019 INDEPENDENT AUDITORS’ REPORT 1 FINANCIAL STATEMENTS Balance Sheet 2 Statement of Operations 3 Statement of Changes in Members’ Equity 4 Statement o

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On January 24, 2020, (the “Closing Date”), Anika Therapeutics, Inc. (the “Company” or “Anika”) completed the acquisition of Parcus Medical, LLC, a Wisconsin limited liability company (“Parcus”) pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Parcus Merger Agreement”), by and among

Arthrosurface, Inc. Condensed Interim Financial Statements Nine Months Ended September 30, 2019 and 2018 Arthrosurface, Inc.

EX-99.2 4 exh992.htm EXHIBIT 99.2 Exhibit 99.2 Arthrosurface, Inc. Condensed Interim Financial Statements Nine Months Ended September 30, 2019 and 2018 Arthrosurface, Inc. Condensed Interim Financial Statements Nine Months Ended September 30, 2019 and 2018 Arthrosurface, Inc. Contents Financial Statements Condensed Balance Sheets 4-5 Condensed Statements of Operations 6 Condensed Statements of Red

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) - Delaware 000-21326 04-3145961 (State or other jurisdiction of Commission file numb

ANIK / Anika Therapeutics Inc. 10-K - Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21326 Anika Therapeutic

List of Subsidiaries of Anika Therapeutics, Inc.

EXHIBIT 21.1 SUBSIDIARIES OF ANIKA THERAPEUTICS, INC. Name of Subsidiary Jurisdiction of Formation Anika Securities Corp. Massachusetts Anika Therapeutics Limited United Kingdom Anika Therapeutics S.r.l. (Formerly: Fidia Advanced Biopolymers S.r.l.) Italy ArthroSurface Incorporated Delaware Parcus Medical, LLC Wisconsin

Form of Notice of Grant of Deferred Stock AwardsUnits, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

Exhibit 10.13(g) NOTICE OF GRANT OF DEFERRED STOCK UNITS ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Anika Therapeutics, Inc. (the “Company”) hereby grants, pursuant to the provisions of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “Plan”), to the Grantee designated in this Notice of Grant of Deferred Stock Units (the “Notice of Grant”

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 Anika Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21326 04-3145961 (State or other (Commission file number) (I.R.S. Employ

Employment Agreement, dated February 25, 2020, by and between Anika Therapeutics, Inc., and Dr. Cheryl R. Blanchard

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 Anika Therapeutics, Inc. 32 Wiggins Avenue Bedford, Massachusetts 01730 February 25, 2020 Dr. Cheryl R. Blanchard [●] Dear Cheryl: On behalf of Anika Therapeutics, Inc. (the “Company”), I am pleased to provide you with this letter agreement (this “Agreement”) setting forth the principal terms of the compensation package to be provided to you by the Co

Anika Reports Fourth Quarter and Full Year 2019 Financial Results Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Rang

EXHIBIT 99.1 Anika Reports Fourth Quarter and Full Year 2019 Financial Results Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Range for Full Year 2020 BEDFORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 20, 2020 Anika Therapeutics (Exact Name of Registrant as Specified in Charter) Delaware 000-21326 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission File N

ANIK / Anika Therapeutics Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* Anika Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 035255108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

EXHIBIT 99.1 Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO BEDFORD, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identi